Scientists at USC Michelson Center for Convergent Bioscience and Japan’s Nagoya University find and test a promising drug that stops cancer by interfering with the cancer cells’ metabolism and other circadian-related functions
A new drug shows potential to halt cancer cells’ growth by stunting the cells’ biological clock.
The findings from scientists at the USC Michelson Center for Convergent Bioscience and Nagoya University’s Institute of Transformative BioMolecules (ITbM) advance a burgeoning area of research: turning the body’s circadian rhythms against cancer.
Their study, conducted on human kidney cancer cells and on acute myeloid leukemia in mice, was published Jan. 23 in the journal Science Advances.
Scientists know that disrupting sleep and other elements of humans’ circadian rhythm can harm health. The same is true for the circadian clock of cells themselves. If researchers could disturb the circadian clock of cancer cells, they theorize, they could potentially hurt or kill those cells.
The scientists found that a molecule named GO289 targets an enzyme that controls the cell’s circadian rhythm. This drug-protein interaction then disrupts the functions of four other proteins that are important for cell growth and survival.
Human bone cancer cells stopped growing when a drug molecule jammed their circadian rhythm during a study that appears in Science Advances. Photo courtesy of the Kay lab at the USC Michelson Center for Convergent Bioscience.
In effect, GO289 can jam the cogs of the cell’s circadian clock, slowing its cycles. And it can do so with little impact to healthy cells.
“In some cancers, the disease takes over the circadian clock mechanism and uses it for the evil purpose of helping itself grow,” said Steve Kay, director of convergent biosciences at the USC Michelson Center and USC Provost Professor of Neurology, Biomedical Engineering and Biological Sciences. “With GO289, we can interfere with those processes and stop the cancer from growing.”
Kay is among several scientists from USC Dornsife College of Letters, Arts and Sciences, USC Viterbi School of Engineering and Keck School of Medicine of USC who are collaborating across multiple disciplines to find new solutions for treating cancer, neurological disease and cardiovascular disease.
Finding the right candidate
On its initial interactions with human bone cancer cells, GO289 appeared to slow the tumors’ circadian clock as it targeted an enzyme, named CK2.
To see if GO289 consistently hindered other cancers in the same way, the scientists then tested it on human kidney cancer cells and on mice with acute myeloid leukemia. They found that GO289 specifically affected cancer cell metabolism and other circadian-related functions that normally would enable the cancer to grow and spread.
Kay is optimistic about the findings. “This could become an effective new weapon that kills cancer,” he said.
The Latest on: Cancer
via Google News
The Latest on: Cancer
- Prostate Cancer and Race on June 16, 2019 at 8:02 am
Over the years, as a staff medical reporter for a large metro daily in Chicago and a freelancer, I have written many stories about health issues affecting African Americans, including access to care, ... […]
- Firefighters battle occupational cancer on June 16, 2019 at 6:09 am
It's one of the most dangerous jobs in the world. Every day firefighters risk their own lives to protect the lives of others. Firefighters like Fire Captain Mike Palumbo. During his more than two ... […]
- Eastenders actor: My dad found out he had cancer after seeing me on TV on June 16, 2019 at 5:03 am
Eastenders star Davood Ghadami has revealed how a chance opportunity to give out an award ended up saving his dad’s life. The actor, who plays Kush in Eastenders, was invited to present an NHS Heroes ... […]
- Cancer survivor completes Royal Windsor triathlon on June 16, 2019 at 4:19 am
A man who was given a six percent chance of survival after being diagnosed with stage 4 cancer has completed his first triathlon. Brian Greenley, 61, underwent treatment for bowel, liver and lung ... […]
- There Will Be Over 22 Million Cancer Survivors In The U.S. By 2030, Says New Report on June 15, 2019 at 6:44 pm
A new report has predicted that there will be 22.1 million people with a personal history of cancer by 2030. The report, produced every three years as a joint venture between the American Cancer ... […]
- Breast cancer taboo 'can cause isolation' for black women on June 14, 2019 at 6:41 pm
A woman who had breast cancer has spoken out about the "isolation" people with the disease from minority ethnic communities can feel. Bamidele Adenipekun, from Swansea, said it was not discussed "due ... […]
- A New Report Says More Americans Are Beating Cancer Than Ever. Is Our Healthcare System Ready? on June 14, 2019 at 11:48 am
Cancer terrifies us. It just does. Especially those of us who grew up when most kinds of cancer meant certain death. And for us it hasn’t seemed to matter that treatments and survival rates speak to ... […]
- Roundup is embroiled in cancer cases. Now its maker is putting $5.6 billion toward a new kind of weedkiller. on June 14, 2019 at 9:33 am
Bayer, the crop science and chemicals giant, said it would invest more than $5.6 billion in weedkiller research and trim its environmental impact — a move that follows three consecutive jury verdicts ... […]
- Breast implants linked to rare form of cancer, but FDA declines to ban on June 14, 2019 at 5:25 am
Anecdotes of a breast implant and cancer connection have sent several foreign governments into a tailspin and raised alarm bells for some recipients, but as it stands the U.S. is refusing to halt the ... […]
- All Blacks Great Lochore Diagnosed With Cancer on June 14, 2019 at 12:42 am
WELLINGTON — Former All Blacks captain and coach Brian Lochore has been diagnosed with bowel cancer, New Zealand Rugby Chief Executive Steve Tew said on Friday. The 78-year-old Lochore, a rugged loose ... […]
via Bing News